Maximum tolerated dose and anti-tumor activity of intraperitoneal cantrixil (Trx-e-002-1) in patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: Phase I study results

Jermaine I. Coward, Minal A. Barve, Ganessan Kichenadasse, Kathleen N. Moore, Paul R. Harnett, Daniel Berg, James S. Garner, Don S. Dizon

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)
48 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Maximum tolerated dose and anti-tumor activity of intraperitoneal cantrixil (Trx-e-002-1) in patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: Phase I study results'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science